Articles

Drug Discovery Technology Market Size Tops USD 80.27 Billion by 2035

BioSpace reports that the drug discovery technology market size is projected to surpass USD 80.27 billion by 2035. This update frames what the figure means for biotech BD teams, investors, and pipeline analysts tracking clinical-trial-linked demand.

Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook

Clinical Trials Outsourcing Market Size is projected to rise from USD 54.38 billion in 2026 to USD 92.81 billion by 2034, reflecting a 6.91% CAGR. This plan highlights the scale, regional lead, and top players most relevant for BD teams, investors, and analysts.

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context, with trial facts, status, and a clear split between active development and regulatory context. This plan is built for analysts, BD teams, and investors comparing clinical-stage autoimmune assets.

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.

Eastern Asia Needle-Free Jet Injection Nozzles Market: Trends, Forecast & Insights

This article provides a comprehensive analysis of the Eastern Asia needle-free jet injection nozzles market, including market size, forecast, key trends, and strategic insights for pharmaceutical companies and investors.

ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds

At ASCO26, Revolution Medicines presented Phase III data for daraxonrasib, demonstrating a dramatic overall survival benefit in previously treated pancreatic ductal adenocarcinoma. This analysis covers the trial results, regulatory milestones, and strategic implications for pharma teams and investors.

Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India: Strategic implications for pharma BD teams

Poly Medicure has appointed Indranil Mukherjee as Chief Executive Officer for Asia Pacific and India, effective June 1, 2026. This move signals a leadership refresh aimed at accelerating regional growth and market penetration.

Cell Therapy Packaging Market Size & Share Report, 2033: Key Trends and Forecasts

The global cell therapy packaging market is set to expand from $404 million in 2025 to $1.27 billion by 2035, driven by robust cell therapy pipeline growth and regulatory requirements. This report provides a competitive benchmarking analysis for pharma professionals.

Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours

Orion Pharma announced first results from the Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 in advanced solid tumours. The drug was well tolerated with no dose-limiting toxicities and a 15.6% overall response rate.

The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains

The Council on Foreign Relations' 'The Pharma Choke Point' report details how U.S. dependence on Chinese pharmaceutical inputs is structural and growing, posing a risk of deliberate supply disruption. This article explains the key findings, implications for pharma teams, and what to watch next.

Ecosystem Over Geography: Life Sciences Location Strategy in APAC

Life sciences companies in Asia-Pacific are shifting from traditional geographic clustering to ecosystem-based location strategies. This article analyzes the key factors driving this change and its implications for strategic planning.

Helus Pharma to Participate in the Jefferies Global Healthcare Conference: Strategic Implications for Analysts and BD Teams

Helus Pharma announced its participation in the Jefferies Global Healthcare Conference in New York, where interim CEO Eric So will deliver a fireside chat. This appearance signals the company's intent to engage with institutional investors and highlight its pipeline progress amid a competitive landscape.

Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide

Kelun-Biotech has secured Investigational New Drug (IND) approval from China's CDE for its novel PD-1 x VEGF bispecific antibody, SKB118. This milestone opens the door for clinical development and presents significant opportunities and competitive considerations for the pharmaceutical industry.

AbbVie Secures FDA Approval for ImmunoGen's Elahere

Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere

Injectable Drug Delivery Market Set for Significant Growth: Insights for Pharma Stakeholders

The global injectable drug delivery market is poised for substantial expansion, projected to grow from an estimated US$655.1 billion in 2026 to US$1182.2 billion by 2033. This rapid growth presents significant opportunities and strategic considerations for pharmaceutical companies.

Acclinate and HCN Global Forge Strategic Partnership to Enhance Clinical Research Diversity

Acclinate and HCN Global have launched a strategic partnership to improve clinical research access and representation for Hispanic and Latino communities. This collaboration leverages Acclinate's NOWINCLUDED platform and HCN Global's established networks to address underrepresentation in clinical trials.

Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026

Minghui Pharmaceutical and Qilu Pharmaceutical Co. have announced updated clinical data from their Phase I/II study of MHB088C (QLC5508) in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. The findings demonstrated encouraging anti-tumor activity and durable disease control.

The Pulse of ACC: Honoring Eugene Braunwald and Shaping Cardiology's Future

The Pulse of ACC commemorates the indelible legacy of Dr. Eugene Braunwald, widely recognized as the father of modern cardiology, particularly for his foundational work in hypertrophic cardiomyopathy. The article also serves as a call for community feedback to guide the future direction of cardiovascular medicine.

Illumina's APAC Strategy Under Nilesh Shah: A Competitive Benchmark

Nilesh Shah's appointment as Head of Region, APAC for Illumina signals a strategic focus on expanding the company's footprint in the dynamic Asian market. This move is poised to influence competitive dynamics within the genomics and diagnostics sectors across the region.

How Medicine Forgot Women: A Missed Opportunity for Asia

For decades, medical research has disproportionately focused on male physiology, leading to a significant gap in understanding and treating diseases in women. As Asia's healthcare landscape evolves, it has a critical opportunity to lead in addressing this historical oversight.